Delivery Order SPE2DB20D9766-SPE2DB25FC1ET

Award Date 1/13/25
Potential Completion Date 2/4/25
Potential Value $5.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $5,567.10, covers the supply of YF-VAX 1 dose vials. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $33,402.60 contract is for the delivery of YF-VAX 1 dose vials, a specialized vaccine product, with a completion date of February 24, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,670.13 contract is for the delivery of 4567790722 units of YF-VAX 1 dose vials, with a completion date of April 15, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,567.10 contract is for the delivery of 4567677932 YF-VAX 1 dose vials, with a performance period ending on March 6, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,113.42 contract is for the delivery of YF-VAX 1 dose vials, a specialized pharmaceutical product, with a performance period ending on March 26, 2025. DMS Pharmaceutical Group Inc. also holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $1,126.98 contract is for the delivery of YF-VAX 1 dose vials, with a period of performance through August 29, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of branded and generic prescription drugs, over-the-counter medications,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,113.42 contract is for the delivery of 4567870435 YF-VAX 1 dose vials, a specialized pharmaceutical product, with a period of performance through April 29, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,701.30 contract is for the supply of 4567419891 YF-VAX 1 dose vials, with a performance period through March 18, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance of delivery orders for a comprehensive range...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,113.42 contract is for the supply of 4567790720 YF-VAX 1 DOSE VIALS and has an ultimate completion date of April 21, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $11,134.20 contract is for the delivery of YF-VAX 1 dose vials, with a performance period ending on April 28, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a wide range of...
  • SPE2DB20D9766
    Indefinite Delivery Contract
  • SPE2DB20D9766-SPE2DB25FC1ET
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,567.10 contract is for the supply of YF-VAX 1 dose vials, a specialized vaccine product. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which covers a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. The contract has no set-aside designation and was awarded on January 13, 2025, with an ultimate completion date of February 4, 2025. As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has consistently demonstrated its capability to provide a diverse array of prescription drugs, over-the-counter medications, biologics, and medical consumables to the Defense Department.

Generated 4/14/25, 10:25 AM